September 21, 2009 – Edwards Lifesciences Corp. today announced new clinical data demonstrating 100 percent freedom from structural deterioration of the Edwards SAPIEN valve at 18 months, as well as positive midterm patient outcomes resulting from the application of learnings from earlier clinical programs.
